Solid Q4 numbers have set ANI Pharmaceuticals, Inc. up for a pivotal 2023, as better-than-expected sales of both generic products and established brands drove up revenue. The firm’s pivotal Cortrophin gel (repository corticotropin injection) 80 U/ml, an adrenocorticotropic hormone therapy indicated for the treatment of a range of chronic autoimmune disorders, has been particularly significant in its success.
2022 was a landmark year for ANI, as both its rare disease and generics segments grew substantially following the Cortrophin...
